

RESPIRATORY FAILURE AND INTERVENTIONS

Amelia Lowell, RRT
Director, Respiratory
Care
Mayo Clinic Hospital
Phoenix, Az



OBJECTIVES

Define	Define respiratory failure and identify the need for non-invasive positive pressure ventilation
Understand	Understand the physical principles of positive pressure ventilation and ventilatory assistance
Manage	Manage a patient on non-invasive positive pressure ventilation
Understand	Understand cardiopulmonary interaction and physiologic consequences of positive pressure ventilation
Review	Review basic mechanical ventilation principles

James Walker

Age 72

MRN 361-440-57

ARTERIAL SAMPLE
 09/25/2013 11:18
 System Name RC4
 System ID 0405-10484
 Acc No [REDACTED]
 Patient ID [REDACTED]
 Operator 32112

ACID/BASE
 pH 7.35
 pCO₂ 55 mmHg
 pO₂ 55 mmHg
 HCO₃⁻act 29 mmol/L
 BE(B) 2.9 mmol/L


CO-OXIMETRY
 Hct 36 %
 tHb 12.4 g/dL
 sO₂ 96.4 %
 FO₂Hb 95.5 %
 FCOHb 0.7 %
 FMetHb 0.2 %
 FHHb 3.6 %

CORRECTED 37.0 °C
 pO₂(A-a)(T) 92.1 mmHg
 pO₂(a/A)(T) 0.50

Temperature 37.0 °C
 F_IO₂ 36.0 %
 pAtm 740 mmHg


PATIENT RANGES
 pH 7.350 - 7.450
 pCO₂ 35.0 - 45.0
 pO₂ 80.0 - 100.0
 tHb 11.5 - 17.5
 FO₂Hb 0.0 - 100.0
 FCOHb 0.0 - 1.9
 FMetHb 0.0 - 0.9
 FHHb 0.0 - 100.0


↓, ↑=Out of range




COPD Exacerbation
 FEV₁ 55%
 70 pyh smoker
 Increased green sputum production

ORDERS
 SVN- Albuterol/Atrovent x 3
 ABG
 Chest Xray
 O2 Therapy






WHY DO WE
BREATHE?



© Copyright 2023 Mayo Foundation for Medical Education and Research




© Copyright 2023 Mayo Foundation for Medical Education and Research

OXYGEN DELIVERY AND OXYGEN CONSUMPTION

NORMAL BREATHING

O₂/CO₂ MOVEMENT




NECESSARY COMPONENTS



Respiratory Pump (V)

Circulatory Pump (Q)

Interface Between the Two




RESPIRATORY PUMP



RESPIRATORY FAILURE

RESULT:
Hypoxemia
and/or
Hypercapnia



RESPIRATORY FAILURE

**Hypoxemic
TYPE I**


*ACUTE
and/or
CHRONIC*

**Hypercapnic
TYPE II**

↓ **SpO₂**
↓ **PaO₂**

↑ **PaCO₂**
↑ **EtCO₂**

TYPE I: HYPOXEMIC RESPIRATORY FAILURE




TYPE II: HYPERCAPNIC RESPIRATORY FAILURE

HYPOVENTILATION

↑ DEAD SPACE VENTILATION

↑ CO₂ PRODUCTION



CHRONIC RESPIRATORY FAILURE

- Results from any of the previously mentioned physiologic processes but sustained for weeks to months
- Often results in chronic metabolic changes seen in an arterial blood gas

Rule of Thumb

Acute Ventilatory Failure

- pH decreases by 0.08 for every 10 mmHg increase in PaCO_2 (from 40)

Chronic Ventilatory Failure

- pH decreases 0.03 for every 10 mmHg rise in PaCO_2 (from 40)

SIGNS OF RESPIRATORY FAILURE

EARLY

Tachypnea

Tachycardia

Hypertension

Use of accessory muscles

↓LOC

↓SpO₂

Circum-oral cyanosis

Nailbed paleness

FAST

LATE

Unconsciousness

Bradycardia

Bradypnea

Hypotension

Generalized cyanosis

SLOW

RESPIRATORY INTERVENTIONS

INTERVENTIONS



Oxygen Therapy



Continuous Positive Pressure Ventilation



Bilevel Positive Pressure Ventilation




Mechanical Ventilation

Non-Invasive

Invasive

HOW TO CHOOSE THE INTERVENTION



Hypoxia

- Oxygen Therapy
- CPAP

Hypercapnia

- Bilevel NIV
- Mechanical ventilation

↑WOB

- High Flow O₂
- Bilevel NIV
- Mechanical Ventilation

Airway Protection

- Mechanical Ventilation

James Walker

Age 72

MRN 361-440-57

ARTERIAL SAMPLE
 09/25/2013 11:18
 System Name RC4
 System ID 0405-10484
 Acc No [REDACTED]
 Patient ID [REDACTED]
 Operator 32112

ACID/BASE
 pH 7.35
 pCO₂ 55 mmHg
 pO₂ 55 mmHg
 HCO₃^{-act} 29 mmol/L
 BE(B) 2.9 mmol/L


CO-OXIMETRY
 Hct 36 %
 tHb 12.4 g/dL
 sO₂ 96.4 %
 FO₂Hb 95.5 %
 FCOHb 0.7 %
 FMetHb 0.2 %
 FHHb 3.6 %

CORRECTED 37.0 °C
 pO₂(A-a)(T) 92.1 mmHg
 pO₂(a/A)(T) 0.50

Temperature 37.0 °C
 F_IO₂ 36.0 %
 pAtm 740 mmHg


PATIENT RANGES
 pH 7.350 - 7.450
 pCO₂ 35.0 - 45.0
 pO₂ 80.0 - 100.0
 tHb 11.5 - 17.5
 FO₂Hb 0.0 - 100.0
 FCOHb 0.0 - 1.9
 FMetHb 0.0 - 0.9
 FHHb 0.0 - 100.0

↓, ↑=Out of range



COPD Exacerbation
 FEV₁ 55%
 70 pyh smoker
 Increased green sputum production

ORDERS
 SVN- Albuterol/Atrovent x 3
 ABG
 Chest Xray
 O2 Therapy



OXYGEN THERAPY



Nasal
Cannula
1-6 LPM

FIO₂ variable- up to 0.44
Not appropriate for patient with high work of breathing



Simple
Mask
7-12 LPM

FIO₂ variable- up to 0.60
Cannot be humidified
Not a great choice for patients with high work of breathing

NRB Mask
10-
15LPM*

FIO₂ variable- up to 0.95
•*Can turn flowmeter up to 40LPM to keep bag inflated
Cannot be humidified
Not appropriate long term



High Flow
Humidified
Oxygen

0.21-1.0 FIO₂ and 20-70 lpm Flow
Independent control of liter flow from FIO₂
Can generate positive end expiratory pressure (PEEP), minimal and variable
Provides high quality gas humidification

LEARNING CHECK

You are called to see a patient for hypoxia :

- 65 year old male post-op left hip replacement on a PCA pump
- Obtunded, not responding to painful stimuli, RR 4
- SpO₂ 78% on NRB mask

WHAT IS THE MOST APPROPRIATE INTERVENTION?

- High flow nasal cannula
- CPAP
- BIPAP

- Bag-mask ventilation and intubation

James Walker

Age 72

MRN 361-440-57

ARTERIAL SAMPLE
 09/25/2013 11:18
 System Name RC4
 System ID 0405-10484
 Acc No [REDACTED]
 Patient ID [REDACTED]

Operator 32112

ACID/BASE
 pH 7.29
 pCO₂ 80 mmHg
 pO₂ 75 mmHg
 HCO₃^{-act} 29 mmol/L
 BE(B) 2.9 mmol/L


CO-OXIMETRY
 Hct 36 %
 tHb 12.4 g/dL
 sO₂ 90 %
 FO₂Hb
 FCOHb 0.7 %
 FMetHb 0.2 %
 FHHb 3.6 %

CORRECTED 37.0 °C
 pO₂(A-a)(T) 92.1 mmHg
 pO₂(a/A)(T) 0.50

Temperature 37.0 °C
 FIO₂ 36.0 %
 pAtm 740 mmHg

PATIENT RANGES
 pH 7.350 - 7.450
 pCO₂ 35.0 - 45.0
 pO₂ 80.0 - 100.0
 tHb 11.5 - 17.5
 FO₂Hb 0.0 - 100.0
 FCOHb 0.0 - 1.9
 FMetHb 0.0 - 0.9
 FHHb 0.0 - 100.0


↓, ↑=Out of range



COPD Exacerbation
 FEV₁ 55%
 70 pyh smoker
 Increased green sputum production

ORDERS

- ✓ SVN-
Albuterol/Atrovent x 3
- ✓ ABG
- ✓ Chest Xray
- ✓ O2 Therapy



WHAT IS POSITIVE PRESSURE VENTILATION?

**HOW DOES THIS
DIFFER FROM
NORMAL
BREATHING?**

NEGATIVE PRESSURE VENTILATION

$P_{\text{atmosphere}} = P_{\text{intrapulmonary}} = 760\text{mmHg}$
(0)

$P_{\text{intrapleural}} = 756\text{mmHg} (-4)$

$P_{\text{transpulmonary}} = 4\text{mmHg}$

Negligible $P_{\text{chest-wall}}$

Pleura

Diaphragm

INSPIRATION

EXPIRATION

ACTIVE


When the diaphragm contracts
 P_{pleural} more negative (-6 mmHg) than
the atmospheric pressure = pressure
gradient high to low =
Gas moves into Lung

PASSIVE

Diaphragm relaxes
 P_{pleural} normalizes (-4 mmHg) =
Gas moves out of the lung

POSITIVE PRESSURE VENTILATION

There is more pressure in the “atmosphere” aka ventilator circuit
Lungs expand due the “artificial” pressure gradient created between the circuit and the airways, does not require a contraction of the diaphragm



PHYSIOLOGIC CONSEQUENCES OF PPV



Gas Exchange

- ↑ alveolar recruitment
- ↑ alveolar surface area
- ↓/- V/Q matching
- ↑/↓ SpO₂ and PaO₂
- ↑/↓ O₂ Delivery



Hemodynamics

- ↓ LV and RV preload
- ↓ LV afterload
- ↑ RV afterload
- ↑/↓ cardiac output
- ↑/↓ blood pressure



Monitoring

- ↑ CVP



NIPPV GOALS

Acute Care

- ❖ **Improve gas exchange**
- ❖ **Avoid Intubation**
 - ❖ **Decrease mortality**
 - ❖ **Decrease ventilator length of stay**
 - ❖ **Decrease length of hospitalization**
 - ❖ **Decrease incidence of ventilator associated pneumonia**
- ❖ **Relieve symptoms of respiratory distress**
- ❖ **Improve patient-ventilator synchrony**
- ❖ **Maximize patient comfort**

Long-Term Care

- ❖ **Relieve or improve symptoms**
- ❖ **Enhance quality of life**
- ❖ **Avoid hospitalization**
- ❖ **Increase survival**
- ❖ **Improve mobility**

PATIENT SELECTION

Acute Conditions

- ❖ **Hypercapnic/Hypoxemic respiratory failure**
- ❖ **COPD exacerbation**
- ❖ **Acute cardiogenic pulmonary edema**
- ❖ **End of life/DNI**
- ❖ **Postoperative respiratory failure**
- ❖ **Prevention of reintubation in high risk patients**
- ❖ **Post extubation respiratory failure**

Chronic Conditions

- ❖ **Nocturnal hypoventilation**
- ❖ **Restrictive thoracic disease**
- ❖ **ALS**
- ❖ **COPD**
- ❖ **Obesity hypoventilation syndrome**

WHO SHOULD **NOT** GO ON NIPPV?

Cardiac arrest/respiratory arrest

Untreated pneumothorax

Non-respiratory organ failure

Facial surgery or trauma

Upper airway obstruction

Inability to protect the airway

High risk for aspiration



LEARNING CHECK

- An 83 year old patient is post-op day 3 from parotid gland resection
- She is audibly gurgling and coughing but unable to expel secretions. Naso-tracheal suction reveals copious amounts of thick, white sputum
- The nurse tells you that she has just been made NPO because she was aspirating her food
- An ABG shows: pH 7.29, PaCO₂ 70, PaO₂ 68, HCO₃ 27

Is she an appropriate candidate for NIPPV? Y or N

Answer: NO, she cannot protect her airway and is at high risk for aspiration and needs aggressive pulmonary toilet. Intubation and mechanical ventilation are more appropriate.

THE EVIDENCE FOR NIPPV

Summary from the
ERS/ATS Clinical Practice
Guidelines

Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Bram Rochweg ¹, Laurent Brochard^{2,3}, Mark W. Elliott⁴, Dean Hess⁵, Nicholas S. Hill⁶, Stefano Nava⁷ and Paolo Navalesi⁸ (members of the steering committee); Massimo Antonelli⁹, Jan Brozek¹, Giorgio Conti⁹, Miquel Ferrer¹⁰, Kalpalatha Guntupalli¹¹, Samir Jaber¹², Sean Keenan^{13,14}, Jordi Mancebo¹⁵, Sangeeta Mehta¹⁶ and Suhail Raoof^{17,18} (members of the task force)

TABLE 2 Recommendations for actionable PICO questions

Clinical indication [#]	Certainty of evidence [¶]	Recommendation
Prevention of hypercapnia in COPD exacerbation	⊕⊕	Conditional recommendation against
Hypercapnia with COPD exacerbation	⊕⊕⊕⊕	Strong recommendation for
Cardiogenic pulmonary oedema	⊕⊕⊕	Strong recommendation for
Acute asthma exacerbation		No recommendation made
Immunocompromised	⊕⊕⊕	Conditional recommendation for
<i>De novo</i> respiratory failure		No recommendation made
Post-operative patients	⊕⊕⊕	Conditional recommendation for
Palliative care	⊕⊕⊕	Conditional recommendation for
Trauma	⊕⊕⊕	Conditional recommendation for
Pandemic viral illness		No recommendation made
Post-extubation in high-risk patients (prophylaxis)	⊕⊕	Conditional recommendation for
Post-extubation respiratory failure	⊕⊕	Conditional recommendation against
Weaning in hypercapnic patients	⊕⊕⊕	Conditional recommendation for

[#]: all in the setting of acute respiratory failure; [¶]: certainty of effect estimates: ⊕⊕⊕⊕, high; ⊕⊕⊕, moderate; ⊕⊕, low; ⊕, very low.

Question	Recommendation	Summary
Should NIV be used in COPD exacerbation?	<p>1) To prevent acute respiratory acidosis, i.e. when the arterial CO₂ tension (PaCO₂) is normal or elevated but pH is normal</p> <p>2) To prevent endotracheal intubation and invasive mechanical ventilation in patients with mild to moderate acidosis and respiratory distress, with the aim of preventing deterioration to a point when invasive ventilation would be considered.</p> <p>3) As an alternative to invasive ventilation in patients with severe acidosis and more severe respiratory distress</p>	Yes
Should NIV be used in ARF due to a COPD exacerbation to prevent the development of respiratory acidosis?	We suggest NIV not be used in patients with hypercapnia who are not acidotic in the setting of a COPD exacerbation. (Conditional recommendation, low certainty of evidence.)	Not to fix compensated chronic respiratory acidosis
Should NIV be used in established acute hypercapnic respiratory failure due to a COPD exacerbation?	<p>We recommend bilevel NIV for patients with ARF leading to acute or acute-on-chronic respiratory acidosis (pH \leq7.35) due to COPD exacerbation. (Strong recommendation, high certainty of evidence.)</p> <p>We recommend a trial of bilevel NIV in patients considered to require endotracheal intubation and mechanical ventilation, unless the patient is immediately deteriorating. (Strong recommendation, moderate certainty of evidence.)</p>	Yes

SUMMARY ERS/ATS RECOMMENDATIONS FOR NIV UTILIZATION

SUMMARY ERS/ATS RECOMMENDATIONS FOR NIV UTILIZATION

Question	Recommendation	Summary
Should NIV be used in ARF due to cardiogenic pulmonary edema?	We recommend either bilevel NIV or CPAP for patients with ARF due to cardiogenic pulmonary edema. (Strong recommendation, moderate certainty of evidence.)	Yes
Should NIV be used in ARF due to acute asthma?	Given the uncertainty of evidence we are unable to offer a recommendation on the use of NIV for ARF due to asthma.	Not sure
Should NIV be used for ARF in immunocompromised patients?	We suggest early NIV for immunocompromised patients with ARF. (Conditional recommendation, moderate certainty of evidence.)	Yes
Should NIV be used in de novo ARF?	Given the uncertainty of evidence we are unable to offer a recommendation on the use of NIV for de novo ARF.	Not sure
Should NIV be used in ARF in the post-operative setting?	We suggest NIV for patients with post-operative ARF. (Conditional recommendation, moderate certainty of evidence.)	Yes
Should NIV be used in patients with ARF receiving palliative care?	We suggest offering NIV to dyspneic patients for palliation in the setting of terminal cancer or other terminal conditions. (Conditional recommendation, moderate certainty of evidence.)	Yes
Should NIV be used in ARF due to chest trauma?	We suggest NIV for chest trauma patients with ARF. (Conditional recommendation, moderate certainty of evidence.)	Yes

SUMMARY ERS/ATS RECOMMENDATIONS FOR NIV UTILIZATION

Question	Recommendation	Summary
Should NIV be used in ARF due to pandemic viral illness?	Given the uncertainty of evidence we are unable to offer a recommendation for this question.	Not sure *consider aerosolizing virus and resource limitations for infection control
Should NIV be used in ARF following extubation from invasive mechanical ventilation?	=We suggest that NIV be used to prevent post-extubation respiratory failure in high-risk patients post-extubation. (Conditional recommendation, low certainty of evidence.)	Yes for high risk No for low risk
Should NIV be used to prevent respiratory failure post-extubation?	We suggest that NIV should not be used to prevent post-extubation respiratory failure in non-high-risk patients. (Conditional recommendation, very low certainty of evidence.)	
Should NIV be used in the treatment of respiratory failure that develops post-extubation?	We suggest that NIV should not be used in the treatment of patients with established post-extubation respiratory failure. (Conditional recommendation, low certainty of evidence.)	No- reintubation is recommended
Should NIV be used to facilitate weaning patients from invasive mechanical ventilation?	We suggest NIV be used to facilitate weaning from mechanical ventilation in patients with hypercapnic respiratory failure. (Conditional recommendation, moderate certainty of evidence.) We do not make any recommendation for hypoxemic patients.	Yes for respiratory acidosis Not sure for hypoxemic

NIV AND ARDS

Non-invasive Ventilation (NIV) of Patients with ARDS: Insights from the LUNG SAFE Study AJRCOJ 2016 Oct

- 436/2813 (15.5%) of ARDS patients were initially managed with NIV regardless of severity
- **NIV use independently associated with under recognition of ARDS 23.2%**
- **NIV Vt too large**
 - 8.46 ± 2.77 ml/kg vs. 7.53 ± 1.75 ml/kg invasive MV ($p < .001$)
- **NIV PEEP inadequate**
 - NIV $7\text{cmH}_2\text{O} \pm 2$ vs. $8\text{cmH}_2\text{O} \pm 3.1$ invasive MV ($p < .001$)
- NIV failure occurred in 22.2% of mild, 42.3% moderate, 47.1% severe ARDS
- ICU mortality 10.6% NIV success vs. 42.7% NIV failure ($p < .001$)
- Hospital mortality 16.1% NIV success vs. 45.4 % NIV failure ($p < .001$)
- **ICU Mortality P/F <150: NIV 36.2% vs. 24.7% Invasive MV ($p = 0.033$)**

Conclusions: NIV was used in 15% of patients with ARDS, irrespective of severity category. NIV appears to be associated with higher ICU mortality in patients with a $\text{PaO}_2/\text{FiO}_2$ lower than 150 mmHg.

NIV/NHF IN ARDS

1. **Recognize ARDS !**
2. Be careful ! (pt selection)
3. NIV settings to target
 - a) IPAP: tidal volume (Vt) 6-8 ml/kg PBW
 - b) EPAP: SpO2 88-95% with lowest FiO2
4. NHF setting: Highest flow lowest FiO2
5. **Closely monitor for 1-6 hours!**
 - a) Work of breathing:
 - a) Accessory muscles
 - b) Respiratory rate
 - b) High likelihood of failure:
 - a) $\text{P/F} \leq 175$ after 1 hr
 - b) $\text{Vt} > 9.5$ ml/kg PBW



Role of Noninvasive Ventilation in
Acute Lung Injury/Acute Respiratory Distress Syndrome:
A Proportion Meta-analysis

Respir Care 2010;55(12):1653-1660

LEARNING CHECK

A 75 year old male is in the Emergency Room with an exacerbation of his congestive heart failure after eating Thanksgiving dinner. The provider calls you to draw an arterial blood gas and place BIPAP on the patient. Your assessment reveals audible bilateral crackles, RR 30, SpO₂ 85%. He is awake and alert and complains of dyspnea.

- The ABG results are: pH 7.35, PaCO₂ 45, PaO₂ 50, HCO₃ 26

Q₁: Is this patient appropriate for NIPPV?

YES

Q₂: What mode of NIPPV will best treat his symptoms?

- S/T (BIPAP)
- CPAP
- AVAPS
- PCV

NON-INVASIVE POSITIVE PRESSURE VENTILATION

Initiation, Management,
and Weaning

INITIATION



- ❖ **Determine mask/interface**
- ❖ **Determine MODE**
- ❖ **Choose INITIAL SETTINGS based on GOALS**
- ❖ **Apply Necessary Monitoring**
- ❖ **Adjust Settings as needed**

INTERFACES

- Mask types
- Headgear selection
- Soft, self-sealing cushions
- Anti-asphyxia features



WOUND PREVENTION- NIV RELATED PRESSURE INJURY

Incidence of skin breakdown

- Localized areas of tissue necrosis
- Develop when soft tissue is compressed between a bony prominence surface for an extended period of time

Most common on bridge of nose!

Extreme cases involve surrounding areas, like over the nose but also on the chin

In literature⁸

Location	Number of pressure ulcers
Nasal bridge	15
Nasolabial fold	2
Cheek	2
Scalp	1
Nasal bridge and nasolabial fold	2

Figure 2. Location of pressure ulcers.

Results

- 20% of patients in the oro-nasal masks developed a pressure injury
- 2% of patients in the full-face masks developed a pressure injury
- Comfort scores significantly lower in the Full-face mask group


Conclusion:
Full-Face mask resulted in significantly fewer pressure injuries and was more comfortable for patients.

Use	Use a skin barrier device for all patients undergoing continuous NIV
Assess	Assess the skin under the mask at each system check
Ensure	Ensure the leak rate is appropriate (7-30 LPM)
Rotate	Rotate the type of mask if injuries are developing
Consult	Consult the wound care nursing team if evidence of a wound is present

⁸Schallom M, Cracchiolo L, Faliker A. Pressure ulcer incidence in patients wearing nasal-oral versus full-face noninvasive ventilation masks. American Journal of Critical Care Medicine. 2015;24(4):349-356.

MODE OF VENTILATION- CPAP OR BILEVEL?

Define the ventilatory defect and cause of failure to determine the best mode




CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE)

Oxygenation


- Improves FRC
- CPAP can be used to improve oxygenation if the patients work of breathing is not high
 - CPAP fails to support inspiratory volume delivery so will provide insufficient support for high work of breathing

Congestive Heart Failure/Cardiogenic Pulmonary Edema

- Use of CPAP recommended



BIPAP (BILEVEL PPV)



IPAP-
VENTILATION
EPAP/CPAP-
OXYGENATION

Ventilation (CO_2)

- Driving pressure to deliver gas (creates the artificial pressure gradient)
- Increase V_t /alveolar ventilation
- Reduce PaCO_2

Oxygenation (O_2)



- Increased resistance to exhalation
- Increased alveolar surface area
- Reduce opening and closing of alveoli each breath
- Mimics physiologic end-expiratory pressure

PRESSURE AND VOLUME RELATIONSHIP


Good rule of thumb:

$$C = \Delta V / \Delta P$$


- Expect > 40 ml of tidal volume for each cmH₂O you add
- Normal compliance = 60-100 ml/cmH₂O



WHAT IS PRESSURE SUPPORT?



Pressure Support= driving pressure
between IPAP and EPAP



Scenario:

1. Initial Settings:

- PS= 5 (IPAP 10/EPAP 5) generates a 5 mL/kg tidal volume
 - *Target Vt 6-8 ml/kg IBW*

2. Modified settings:

- Increased PS to 10 (IPAP 15/EPAP 5) generates a tidal volume of 8 mL/kg

INITIAL SETTINGS

Ventilation	Oxygenation
IPAP (tidal volume)	EPAP
Minute Ventilation (spontaneous RR x Vt)	FIO₂



<https://encrypted-tbn1.gstatic.com/images?q=tbn:ANd9GcTCP4EKzG8Ty60xhxArBal8k5iDcHPxdvJoQ6RtNz1bXQdJYZhuww>

SETTING SELECTION

Setting	Adjustment	Anticipated Result
IPAP	↑	↑ Vt, minute ventilation, ↓ PaCO ₂
	↓	↓ Vt, minute ventilation, ↑ PaCO ₂
EPAP	↑	↑ FRC, ↑ PaO ₂ , ↓ Vt* If intrinsic peep is present, fewer missed triggers and improved patient-ventilator synchrony
	↓	↓ FRC, ↓ PaO ₂ , ↑ Vt*, ↓ PaCO ₂ Possible rebreathing of CO ₂ if EPAP < 4 cmH ₂ O

SETTING SELECTION

Setting	Adjustment	Anticipated Result
FIO ₂	↑	↑ PaO ₂
	↓	↓ PaO ₂
Rate control	↑	↑ minute volume

MONITORING

Tidal
Volume

Work of
Breathing

Arterial
Blood Gas



ACID/BASE	37.0 °C	
pH	7.201↓	
pCO ₂	71.1↑	mmHg
pO ₂	48.8↓	mmHg
HCO ₃ ⁻ act	27.2	mmol/L
BE(B)	-1.0	mmol/L

ASSESSMENT

Goals

↓ **Work of breathing**

RR < 25

HR < 120*

BP stable

Physical work

Deliver adequate tidal volume with PS < 20cmH₂O

Target 6-8 ml/kg of IBW


Improve ABG

Reduce PaCO₂

Improve PaO₂


Normalize pH

ADJUSTMENTS



ADJUSTMENTS

- ❖ 2 cm H₂O ↑↓ max
- ❖ Aggressive weaning of FIO₂ for target SpO₂
- If using BIPAP and EPAP needs to be titrated, IPAP also needs to be titrated to maintain pressure support:



IS IT WORKING?

15 minutes

↓WOB

Vt target achieved
without significant PS
requirement

1 hour

Improving
ABG

↓WOB

Vt stable

@ 4 hours

Stay the
course, wean
or move to
IMV

Consider:

- CXR improvement/worsening
- Hemodynamic improvement/worsening
- Level of consciousness

CONSIDERATIONS

- Need for:
 - Inhaled medication therapy
 - Bronchopulmonary Hygiene
- Mask wound assessment
- NG Tube
- Eating/drinking (aspiration risk/nutrition/pills)
- Communication
- Mobility



[11.3 Oxygenation Equipment – Nursing Skills \(pressbooks.pub\)](#)

WEANING

Consider: when respiratory failure is resolving

Wean IPAP and EPAP

- IPAP: Target 6-8 ml/kg with decreased support
- EPAP: minimum 5 cm H₂O
- Maintain ventilation/oxygenation

Wean FIO₂

- If appropriate; can always support SpO₂ with Oxygen Therapy

Trials off

- When appropriate give the patient a break to eat, drink and do pulmonary toilet

MECHANICAL VENTILATION

Basic Overview

INDICATIONS FOR MECHANICAL VENTILATION

Hypoxic respiratory failure

- Reduce shunt by opening collapsed alveoli
- Delivery high FIO_2

Hypercapnic respiratory failure

- Reduced work of breathing preventing fatigue
- Maintain alveolar ventilation to prevent respiratory acidosis

Excessive Work of Breathing

- Metabolic Acidosis
- Sepsis
- Respiratory failure

Unprotected or Unstable Airway



- Altered level of consciousness
- Surgery

MECHANICAL VENTILATION: GOALS & HARM

NOT CAUSE HARM


CARDIAC risk

Reduced cardiac output
Impaired venous return
Hypotension




GAS EXCHANGE risk


Worsen shunt with unilateral lung disease
Increased dead space



LUNG risk

Barotrauma
Vent induced lung injury
Air trapping





Trigger: Start of inhalation

Target: tidal volume delivery

Cycle: start of exhalation

VENTILATOR MODE IS DEFINED BY WHAT HAPPENS IN THE 3 PHASES OF THE BREATH

CONTROLLED MODES AND BREATH TYPES

Volume
FIXED FLOW

- **Trigger:** machine (set RR) or patient effort
- **Target:** set flow/ V_t
- **Cycle:** set flow/ V_t achieved

Pressure
VARIABLE FLOW

- **Trigger:** machine (set RR) or patient effort
- **Target:** set pressure achieved
- **Cycle:** set inspiratory time

Dual
Pressure regulated,
volume targeted
VARIABLE FLOW

- **Trigger:** machine (set RR) or patient effort
- **Target:** set pressure w/ target V_t achieved
- **Cycle:** set inspiratory time

SPONTANEOUS MODES AND BREATH TYPES


Dual
Pressure
regulated/volume
targeted
VARIABLE FLOW

- **Trigger:** patient effort
- **Target:** Pressure w/ target V_t achieved
- **Cycle:** Exp flow deceleration (%)


Pressure Support
VARIABLE FLOW

- **Trigger:** patient
- **Target:** set pressure
- **Cycle:** Exp flow deceleration (%)

MAYO CLINIC MECHANICAL VENTILATION GUIDE



$$\frac{\text{CURRENT pCO}_2}{\text{DESIRED pCO}_2} = \frac{\text{DESIRED V}_T \text{ or BPM or V}_E}{\text{CURRENT V}_T \text{ or BPM or V}_E}$$




ALARM SETTINGS	MAX	MIN
P _{PEAK}	35	5
V _E	10LPM	4LPM
RATE	25	10
V _T	10 ML/KG	4 ML/KG
LEAK %	OFF	
APNEA	20 S	

* BP Goal may be adjusted according to end organ perfusion and congestion.
 O₂ Goal may be adjusted according to end organ function/oxygen delivery.
 CO₂ Goal may be adjusted to compensate for metabolic acidosis and improve arterial pH.

VENTILATION SETTINGS

Respiratory Rate x Tidal Volume = Minute Ventilation



Initial Settings


Determine appropriate tidal volume
• 6-8 ml/kg ideal body weight

Set respiratory rate to achieve > 5-7 lpm

Adjust for optimal ventilation (PaCO₂)

OXYGENATION SETTINGS

- Select lowest FIO₂ to achieve target SpO₂/PaO₂
- Therapeutic PEEP can be used to increase functional reserve capacity (FRC), increase surface area for gas exchange, reduce atelectrauma
- PEEP minimum should be 5 cmH₂O, and titrated up to effect





Setting	Range	Considerations
PEEP	Min 5cmH ₂ O- Max (patient dependent)	SpO ₂ target Effect on Blood Pressure
FIO₂	Min .21- Max 1.0	SpO ₂ target PaO ₂ target Oxygen Toxicity Reabsorption atelectasis @ 1.0 FIO ₂

LUNG PRESSURE MONITORING

PEAK INSPIRATORY PRESSURE

Pressure it takes to get air from the machine through the big airways




PEEP = Positive end-expiratory pressure (as set on ventilator)
PIP = Peak inspiratory pressure


<https://healthjade.net/peak-inspiratory-pressure/>

PLATEAU PRESSURE


Pressure it takes to hold the alveoli open



EFFECTS OF LUNG PRESSURE ON THE HEART



Autopeep (Intrinsic PEEP)



ACUTE RESPIRATORY DISTRESS





Fig. 1 Therapeutic algorithm regarding early ARDS management (EXPERT OPINION)

OBSTRUCTIVE DISEASE

Initial ventilator settings:

- Mode: Volume- controlled ventilation
- Minute ventilation: <10 l/min
- Tidal volume: 6–10 ml/kg ideal body weight
- Respiratory rate: 10–14 cycles/min
- Plateau pressure: <30 cmH₂O
- Inspiratory flow rate: 80-100 l/min
- Inspiratory flow waveform: Decelerating waveform
- Expiratory time: 4–5 s
- PEEP: 5 cmH₂O
- FIO₂: SaO₂ of $>90\%$



WEANING AND EXTUBATION

WHEN TO CONSIDER *EXTUBATION*



Resolution of Disease

- ABG
- CXR
- Minimal vent settings (PS 10/peep5/FIO2 0.40)

Sedation

- Sedation vacation
- Minimal sedation

Hemodynamic Stability

- Off pressors *

WEANING PARAMETERS

MCH Specific (assessed on SPONT PS 0/peep 5):


NIF > -25



Vital Capacity >
10 ml/kg IBW



Tidal Volume > 5
ml/kg IBW



EXTUBATION

Assemble equipment


- Nasal cannula
- Oral suction
- Syringe
- Towel

Instruct the patient to cough

Deflate the cuff, remove the tube

Suction the mouth

Apply oxygen therapy



CONCLUSIONS



Early recognition and accurate identification of the type of respiratory failure is key to treatment



The type of failure, the patient's symptoms and considering the evidence will help determine the appropriate intervention



Settings selection and adjustments should be targeted to improve ventilation, oxygenation, patient comfort and balanced with hemodynamic considerations

REFERENCES (NOT REFERENCED IN TEXT)

1. Rochweg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J*. Aug 2017;50(2)doi:10.1183/13993003.02426-2016
2. Kacmarek RM, Stoller JK, Heuer AJ, Chatburn RL, Kallet RH. *Egan's fundamentals of respiratory care*. Edition 12. ed. Elsevier; 2021:xiv, 1378 pages.
2. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med*. Feb 19 2015;372(8):747-55. doi:10.1056/NEJMs1410639